Immunogenetics: Open Access

Immunogenetics: Open Access
Open Access

+44 1223 790975

Image Article - (2020)Volume 5, Issue 2

Multiple Sclerosis Treatment

Zhou Fan*
*Correspondence: Zhou Fan, Department of Clinical Immunology, Akita University School of Medicine, Japan, Email:

Author info »

Letter to Editor

Treatment of Multiple Sclerosis (MS) has 2 aspects: Immunomodulatory Therapy (IMT) for the underlying immune disorder and therapies to relieve or modify symptoms. IMT is directed toward reducing the frequency of relapses and slowing progression. Currently, most disease-modifying agents have been approved for use only in relapsing forms of MS. Mitoxantrone is also approved for the treatment of secondary (long-term) progressive and progressive relapsing MS. People with advanced MS have severe MS symptoms. In most cases, people with advanced MS are nonambulatory. This means they cannot walk or get around without help from another person or a motorized device. Also, people at this stage have an increased risk of developing other health conditions such as osteoporosis or epilepsy.

People with advanced MS can still benefit from PT. For instance, PT can help you learn to sit properly, develop upper body strength, and maintain the ability to use mobility aids. Although therapy for Clinically Isolated Syndrome (CIS) (a single episode of neurologic symptoms) with immunomodulatory medications has not yet become standard practice throughout the world, trials such as the TOPIC trial suggest that early intervention may be appropriate. Decisions regarding early treatment of relapsing MS can be guided by using the McDonald diagnostic criteria.

The Optic Inflammation Treatment Trial (OPTT) established the quality of care. High dose blood vessel (IV) alkyl glucocorticoid in a very dose of one g/day for three days followed by a brief course of oral steroids in tapering dose was shown to be considerably higher than oral corticosteroids within the fast rate of recovery following mono ocular optic inflammation. Time to next relapse was conjointly prolonged in those that received channel steroids this impact wasn't vital when the primary ten years following OPN. Most neurologists use IV alkyl glucocorticoid in doses of one g/day for 3–5 days. Oral taper with corticosteroids could be a disputed space in MS medical specialty, with several neurologists preferring to avoid it. In some things once patients don't respond well to initial 3–5 days of channel alkyl glucocorticoid, the course is also recurrent once more. It's conjointly best to grant no more than 3 courses of steroids annually in MS patients. Transient hyperglycaemia and sickness} ought to be looked out for and then conjointly worsening of pre-existent acid organic process disease. The particular precaution to be taken before steroid administration is to exclude infections notably urinary pheresis and blood vessel immune serum globulin don't seem to be normal recommendations within the treatment of MS relapse.

Declaration of funding

This study had no funding resources.

Adherence to national and international regulations

Not applicable.

Authors’ contributions

All authors read and approved the final manuscript.



Consent for publication

The authors declare that they have no competing interests.

Competing interests

The authors declare that they have no competing interests.

Author Info

Zhou Fan*
Department of Clinical Immunology, Akita University School of Medicine, Akita, Japan

Citation: Fan Z (2020) Multiple Sclerosis Treatment. Immunogenet Open Access. 5:130.

Received: 14-Oct-2020 Accepted: 29-Oct-2020 Published: 05-Nov-2020 , DOI: 10.35248/igoa.20.5.130

Copyright: © 2020 Fan Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.